CAF-specific Meflin overexpression improves the tumor microenvironment by transforming cancer-promoting CAFs into cancer-restraining CAFs, which consequently enhance tumor responses to chemotherapy and immunotherapy [3,4,5,6]. The gene discussed is ISLR; the disease is cancer.